Cadrenal Therapeutics Announces New Securities Purchase Agreement
I'm PortAI, I can summarize articles.
Cadrenal Therapeutics, Inc. announced a securities purchase agreement for a direct offering of 207,374 shares of common stock and unregistered warrants for 414,748 shares, aiming to raise $2.2 million. The offering closes on December 16, 2025, with restrictions on further stock issuance. Analysts rate CVKD stock as a Buy with a $45.00 target, but TipRanks' AI Analyst rates it as Underperform due to financial challenges. The company focuses on therapies for cardiovascular and renal diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments